Evidence map›Paper›PMID 41436908›Full record

ReviewCurrent HIV/AIDS reports2025

Mycoplasma Genitalium - Where are we at?

Catriona S Bradshaw, Kay Htaik, Ryan Horn, Lenka A Vodstrcil

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current HIV/AIDS reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Catriona S BradshawSchool of Translational Medicine, Monash University, Carlton, VIC, Australia. Catriona.bradshaw@monash.edu.
Kay HtaikSchool of Translational Medicine, Monash University, Carlton, VIC, Australia.
Ryan HornSchool of Translational Medicine, Monash University, Carlton, VIC, Australia.
Lenka A VodstrcilSchool of Translational Medicine, Monash University, Carlton, VIC, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review outlines trends and impact of antimicrobial resistance (AMR) on management strategies for Mycoplasma genitalium and provides a contemporary understanding of its association with sequelae. RECENT

findingsGlobal rises in macrolide- and fluoroquinolone-resistance mean resistance-guided strategies are integral to improving antibiotic use and cure and underpin the importance of emerging AMR surveillance. Incremental progress has been made in improving cure using available generic drugs, often in combination and prolonged regimens. Current data supports an association between M. genitalium and pelvic inflammatory disease, but further research is needed to generate a robust evidence-base for sequelae in women and men. Clinicians are increasingly encountering M. genitalium infections that are challenging to cure. There is an urgent need for investment and support in the development and evaluation of new resistance-diagnostics, new classes of antimicrobials and co-ordinated global AMR surveillance, to enable timely public health responses that inform clinical practice.

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialMycoplasma genitaliumMycoplasma InfectionsFemaleHumansMacrolidesMalePelvic Inflammatory DiseaseAnti-Bacterial AgentsMacrolidesAntibioticsAntimicrobial resistanceManagementMycoplasma genitaliumResistance-assays

Identifiers

PMID41436908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.